Comprehensive clinical reference for neuro-oncology nursing across GCC healthcare settings. Covers WHO 2021 classification, assessment, treatment, symptom management, and end-of-life care.
The 2021 WHO Classification of Tumours of the Central Nervous System (5th edition) introduced major revisions incorporating molecular markers alongside histology. Tumour type now integrates both morphological and genomic features into a single integrated diagnosis.
Diagnosis = Histological type + Molecular markers + WHO Grade. Example: "Glioblastoma, IDH-wildtype, WHO grade 4" — not simply graded by appearance alone.
Arise directly from brain parenchyma, meninges, or supporting structures. Account for approximately 30% of all brain tumours in adults.
Most common intracranial tumours overall. Arise from systemic malignancy spreading haematogenously to the brain. The blood-brain barrier is disrupted at metastatic sites.
Lung (most common — NSCLC, SCLC) • Breast (esp. HER2+ and triple-negative) • Melanoma (high predilection for CNS) • Renal cell carcinoma • Colorectal
Brain metastases are typically multiple, well-circumscribed, ring-enhancing on MRI, located at grey-white matter junction. Single metastasis may be resected.
Arise from arachnoid cap cells of meninges. Most common primary intracranial tumour in adults. Not a glioma — extra-axial (outside brain parenchyma).
Surgery is curative for accessible Grade I. Observation for small asymptomatic lesions in elderly patients.
Embryonal tumour. Most common malignant paediatric brain tumour. Arises in the posterior fossa (cerebellum/4th ventricle). Can seed the entire CSF (leptomeningeal dissemination).
Arises from ependymal cells lining ventricles and spinal canal. Graded I–III. Molecular classification now used (ZFTA fusion, YAP1 fusion, etc.). Important cause of spinal cord tumours.
Primarily diffuse large B-cell lymphoma. Periventricular predilection. Treat with high-dose methotrexate — avoid steroids before biopsy (steroid-sensitive, will cause regression and non-diagnostic biopsy).
| Category | Location | Examples |
|---|---|---|
| Extradural | Outside dura mater | Metastases (most common), lymphoma, myeloma |
| Intradural Extramedullary | Inside dura, outside cord | Meningioma, schwannoma, neurofibroma |
| Intramedullary | Within spinal cord | Ependymoma (most common adult), astrocytoma |
New back pain in cancer patient = exclude MSCC. Dexamethasone 16 mg stat, urgent MRI, RT/surgery within 24h.
| Location | Key Symptoms | Clinical Notes |
|---|---|---|
| Frontal Lobe | Personality change, executive dysfunction, disinhibition, contralateral limb weakness (motor cortex), incontinence | Often subtle and missed early. Family may notice before patient. Dominant: expressive aphasia (Broca's area) |
| Temporal Lobe | Memory impairment, complex partial seizures, contralateral superior quadrantanopia | Dominant hemisphere (usually left): Wernicke's aphasia — fluent but non-sensical speech. Mesial temporal: memory loss, deja-vu aura |
| Parietal Lobe | Contralateral hemisensory loss, spatial neglect, agraphia, acalculia, apraxia | Non-dominant (usually right): hemispatial neglect — patient ignores left side. Gerstmann syndrome (dominant): finger agnosia, acalculia, agraphia, L-R disorientation |
| Occipital Lobe | Contralateral homonymous hemianopia, visual hallucinations, cortical blindness | Patient may not notice visual field defect (anosognosia). Check visual fields carefully in assessment |
| Posterior Fossa / Cerebellum | Ipsilateral limb ataxia, gait ataxia, dysarthria, nystagmus, intention tremor | Cerebellar signs are ipsilateral to lesion. Midline (vermis): truncal ataxia, wide-based gait. Risk of hydrocephalus from 4th ventricle obstruction |
| Brainstem | Multiple cranial nerve palsies, "crossed" deficits (ipsilateral face + contralateral body), dysphagia, dysarthria, locked-in syndrome | Crossed deficits pathognomonic of brainstem lesion. Often inoperable — biopsy via stereotactic approach. Diffuse intrinsic pontine glioma (DIPG) in children |
| Corpus Callosum | Alien hand syndrome, disconnection syndromes, rapid cognitive decline | "Butterfly glioma" — GBM crossing corpus callosum. Poor prognosis |
Monro-Kellie doctrine: the skull is a rigid box. Any increase in volume (tumour + oedema) must be compensated by reduction in CSF or venous blood. Once compensatory mechanisms fail, ICP rises exponentially.
Normal ICP: 5–15 mmHg. Sustained >20 mmHg is pathological. Cerebral perfusion pressure (CPP) = MAP – ICP; target CPP >60 mmHg.
1. Hypertension (widened pulse pressure) • 2. Bradycardia (reflex) • 3. Irregular / slow respirations (Cheyne-Stokes)
This is a very late sign indicating imminent transtentorial herniation. Immediate action required.
Seizures occur in 30–50% of patients with brain tumours (highest with low-grade gliomas in cortical locations). Can be the presenting symptom or develop during treatment.
Lorazepam IV/IM 4 mg (or midazolam buccal 10 mg). If no IV: midazolam buccally. Second line: levetiracetam IV, valproate IV, phenytoin IV. Refractory: ICU, propofol/midazolam infusion. Check glucose.
Not routinely recommended pre-operatively unless history of seizure. Post-operatively in craniotomy patients — often levetiracetam for short period. Not recommended long-term in seizure-free patients.
Eye opening (1–4) + Verbal response (1–5) + Motor response (1–6). Maximum 15 = fully conscious. Score <8 = intubation threshold. Document component scores (E3V4M6 = 13), not just total.
Gold standard for brain tumour imaging. Gadolinium enhancement indicates blood-brain barrier breakdown. Ring enhancement differential: GBM vs brain abscess vs metastasis vs radiation necrosis — clinical context and MR spectroscopy/perfusion used to differentiate.
Used when tumour is in or adjacent to speech, language, or motor cortex. Patient must be awake and cooperative during tumour resection to enable continuous cortical mapping. Requires:
• Rigorous pre-operative psychological preparation
• Detailed discussion of what to expect (noise, sensations)
• Patient performs tasks: naming, reading, motor tasks
• Asleep-awake-asleep protocol or monitored anaesthesia care (MAC)
• In GCC: language considerations (Arabic, Urdu, Hindi) — neuropsychology assessment in patient's primary language essential
GCS (document components) • Pupil size and reactivity bilaterally • Limb power (MRC scale) • Speech assessment • Blood pressure, HR, SpO2, temperature • Wound inspection • Drain output
Brain tumour patients have very high VTE risk (Khorana score, tumour type, immobility). However, post-craniotomy LMWH timing is delayed due to intracranial bleeding risk. Typical protocol:
Most commonly used corticosteroid in brain tumour management. Reduces vasogenic oedema by stabilising the blood-brain barrier. Does not treat the tumour itself.
Standard of care since 2005. Concurrent chemoradiotherapy followed by adjuvant chemotherapy:
MGMT (O6-methylguanine-DNA methyltransferase) is a DNA repair enzyme. Methylation of the MGMT promoter silences the gene, preventing DNA repair after TMZ alkylation — tumour becomes more sensitive to TMZ.
TMZ causes lymphopenia, particularly CD4 T-cell depletion. Check FBC before each cycle. If CD4 <200 cells/μL: increased risk of Pneumocystis jirovecii pneumonia (PCP).
Advantages: broad spectrum, no cytochrome P450 induction (critical — does not reduce chemotherapy/steroid efficacy), no therapeutic drug monitoring required, available IV for post-operative/unable to swallow, renal excretion. Side effects: mood changes/irritability ("Keppra rage") — counsel patient/family; psychiatric history screen.
Cognitive impairment in brain tumours results from tumour location, oedema, surgical injury, RT effects, and chemotherapy. Affects quality of life profoundly — often more distressing to patients than physical deficits.
Any patient with brain tumour-related seizures must not drive until seizure-free for the required period (varies by country). In GCC: inform patients of legal obligations. Document advice given in nursing notes.
Brain tumour patients have very high falls risk (weakness, ataxia, seizures, cognitive impairment, steroid myopathy, fatigue). NICE falls prevention principles apply:
Depression and anxiety are significantly more prevalent in brain tumour patients than other cancer populations. Rates of clinically significant depression: 30–45%. Anxiety: 30–40%. Contributing factors: uncertainty of prognosis, cognitive changes, loss of independence, role changes, fear of seizures.
Family caregivers of brain tumour patients experience exceptionally high burden due to personality and behavioural changes (frontal lobe effects), cognitive changes, seizures, and the prolonged trajectory. Offer:
Symptom deterioration during dexamethasone weaning may indicate: (1) disease progression — rescan, or (2) steroid withdrawal — increase dose temporarily then wean more slowly. Clinical assessment and imaging guide decision. Avoid abrupt cessation.
GBM median survival 14–16 months from diagnosis (Stupp protocol). Trajectory is relatively predictable but sudden deterioration can occur from seizures, haemorrhage, or hydrocephalus.
Unlike many cancers, GBM may cause cognitive impairment early, limiting capacity. ACP conversations must begin early, while capacity is preserved. Do not defer until decline — by then patient may lack capacity to express preferences.
Clinical indicators of the last weeks/days in GBM:
The 2–3 week rapid decline pattern is characteristic of GBM end-of-life. Families should be gently prepared for this trajectory.
ACP should begin at the earliest appropriate opportunity — often at point of diagnosis or soon after. Check mental capacity at each conversation. Document clearly.
In GBM, DNACPR is appropriate to discuss when KPS <50 or at progression on second-line treatment. Frame as: "If your heart were to stop, CPR is very unlikely to restart it given your illness, and we want to focus on comfort." Document sensitively. In GCC: cultural and religious context (Islamic perspective on prolonging life vs. allowing natural death — engage with chaplaincy/family).
Benefits: reduces cerebral oedema, may briefly improve neurological function and comfort. Harms at end of life: Cushing's syndrome, infections, hyperglycaemia, proximal weakness, insomnia.
If patient is in last days of life, is unconscious, or there is no benefit evident: taper and discontinue. If maintaining comfort, continue at lowest effective dose via SC if oral route lost.
Seizures are common in the last days of GBM. Anticipatory medications must be prescribed and readily available:
Frontal lobe disinhibition, personality changes, and cognitive decline cause profound grief and distress for families — often described as "losing the person before they die" (pre-death grief/anticipatory grief). Nursing role: validate these feelings, explain the neurological basis, offer specialist psychological support, and connect with brain tumour support organisations.
Brain tumour incidence in the GCC mirrors global trends but with regional considerations. Brain and CNS cancers represent approximately 1.5–2.5% of all cancer diagnoses in GCC countries. GBM remains the most common malignant primary brain tumour across the region.
| Centre | Country | Capability |
|---|---|---|
| King Fahd Medical City (KFMC) | Saudi Arabia | Comprehensive neuro-oncology, Gamma Knife SRS, awake craniotomy |
| King Faisal Specialist Hospital & Research Centre (KFSH&RC) | Saudi Arabia | Tertiary neurosurgery, proton therapy, molecular tumour board |
| Cleveland Clinic Abu Dhabi | UAE | Full neuro-oncology programme, Gamma Knife, CyberKnife |
| Hamad Medical Corporation (HMC) | Qatar | National Neuroscience Institute, comprehensive neuro-oncology |
| American Hospital Dubai / Mediclinic City | UAE | Neurosurgery, stereotactic procedures |
| Royal Hospital Oman | Oman | National tertiary neurosurgery centre |
GCC countries have among the highest T2DM prevalence globally (UAE ~19%, Saudi Arabia ~18%, Qatar ~16%). Dexamethasone significantly worsens glycaemic control. Monitor blood glucose QDS during dexamethasone use. Proactive insulin prescribing is often required. Liaise with endocrinology/diabetes team early.
Clinical decision support tool for nursing assessment of patients with brain tumours. Answer each question based on current clinical findings, then calculate the ICP concern level.
Click on an answer to reveal whether it is correct and the explanation.